With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...

Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease ...

The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

In terms of competition, there are currently only two other IL-23 inhibitors approved in the US besides Tremfya – Eli Lilly’s Omvoh (mirikizumab) and AbbVie’s Skyrizi (risankizumab).

Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...

The European Commission will review the CHMP recommendation to determine issuing an expanded Marketing Authorisation, and a decision is expected in due course. 2 J&J Data on file (RF-452642). European ...

US healthcare conglomerate Johnson & Johnson appears to have a promising IL-23-blocking oral peptide on its hands in the ...

Pharma brands achieved the most impressions from ABC and saw a year-over-year increase in impressions from cable channels like Fox News, CNN and MSNBC.